pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 16·1 min read
save

Venom’s hidden potential fuels next wave of peptide medicines beyond GLP-1 weight-loss drugs

Jul 16, 2026·read at STAT ↗Positive

Steve Midway, an associate professor at LSU, argues that many powerful medicines already exist in the venoms of feared creatures, noting that venom contributed to the development of GLP-1 based weight-loss drugs.

While most people associate venoms with lethal toxicity-citing the inland taipan’s tiny dose that can kill a human-researchers are increasingly seeing them as a source of therapeutic molecules.

Over millions of years evolution has honed venom components in snakes, lizards, fish, scorpions and many other animals, creating a diverse library that drug developers are beginning to explore.

Midway suggests that this "fang-to-pharmacy" pipeline is only at its start and could expand the peptide-drug era beyond current treatments.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: The growing fang-to-pharmacy pipeline”

read at STAT ↗
1,247 words · retrieved Jul 16
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
BRISTOLBRISTOL MYERS SQUIBBBRISTOL MYERS SQUIBB COUNIQUE
drugs
Obesity2captopril2ziconotide2ImmunologyMOUNJAROOzempicRNS-60WegovyZEPBOUNDexenatidetirzepatide
topics
Hematology6Peptide Therapeutic6Obesity4Oncology4GLP-1 receptor3Pain3Breast CancerCardiologyDermatologyHeart FailureHypertensionImmunologySmall MoleculeType 2 Diabetes

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • 20h agoGSK laying off 1.2K+ in BelgiumBioSpace
  • Dec 22Fierce Biotech Fundraising Tracker '26: OMass obtains $310M; Soufflé cooks up $135MFierce Biotech
  • Sep 29Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand HengruiFierce Biotech
  • Aug 28STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and moreSTAT